# TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278

> **NCT01031589** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 19 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TMC278 (Rilpivirine) LA; Placebo

## Key facts

- **NCT ID:** NCT01031589
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2012-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031589, "TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01031589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*